Project Grant R01HL180887
Award Date 8/19/25
Completion Date 5/31/29
Dollars Obligated $817K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This Project Grant award of $777,258 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to advance the understanding of heart failure in hypertrophic cardiomyopathy (HCM) and evaluate the impact of the cardiac myosin inhibitor mavacamten compared to surgical myectomy. The research, to be conducted by Beth Israel Deaconess Medical Center, Inc. from February 2025 through January 2030, will utilize cardiac magnetic resonance imaging...
- This $385,381 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of dynamic biological hydrogels to modulate cardiac remodeling following myocardial infarction. The primary goals are to: 1) Improve the mechanical stability and stiffness of cardiac extracellular matrix hydrogels compared to existing therapies, and 2) Leverage changes in extracellular matrix composition to promote a more regenerative...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $777,674 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to build the largest echocardiography registry in the world and apply advanced causal inference methods to measure the effects of guideline-directed medical therapies on mortality in patients with heart failure and mid-range ejection...
- The federal Project Grant award of $507,000.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop an automated system that integrates micro-electromechanical sensors, automation, and machine vision to simultaneously measure electrophysiological properties and contractile forces in single human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). This innovative system is expected to significantly reduce measurement time...
- This $834,249 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a comparative study of clinical outcomes, patient experiences, and mechanistic insights between transcatheter and surgical treatment of degenerative mitral regurgitation (DMR). The study aims to provide long-term data on clinical effectiveness, safety, and patient-reported outcomes to inform treatment selection and guide patient care. It will also utilize...
- This $298,368 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of a novel device for treating mitral valve regurgitation. The project aims to optimize the device design and procedure through bench testing, followed by acute in vivo studies to demonstrate the feasibility of the approach. The funding recipient, Link Medical LLC, has invented a catheter-based technology intended to restore proper mitral...
- This Project Grant award of $784,362.00, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Brigham & Women's Hospital Inc., will support research investigating the role of body composition, coronary microvascular dysfunction, and heart failure with preserved ejection fraction in characterizing adverse cardiometabolic disease phenotypes. The research aims to leverage novel imaging technologies to identify mechanisms of...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $165,672 to New York University School of Medicine to conduct research aimed at increasing heart transplant (HT) volume in the United States. The key objectives are to: Investigate the impact of donor risk factors, such as coronary artery disease, left ventricular dysfunction, and older age, on post-HT outcomes using European and U.S. registry data. This...
- This federal Project Grant award of $193,984 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the interplay between inflammation, angiogenesis, myocardial perfusion, and myocardial function in patients with advanced chronic kidney disease (CKD). The project, conducted by Brigham & Women's Hospital Inc., aims to mechanistically explore cardiovascular health before and after kidney transplantation. Key objectives...
- The federal Project Grant award of $131,886 was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, to conduct research on the use of bioimpedance as a tool to assess volume status and predict cardiovascular outcomes in patients with chronic kidney disease. The study aims to 1) examine the predictive capacity of changes in volume measured by bioimpedance for...